Loading...
Market
Story
Biogen Offers $469 Million for Sage Therapeutics at $7.22 Per Share, a 30% Premium
Jan 10, 2025, 11:25 PM
Biogen Inc. has made an unsolicited nonbinding offer to acquire Sage Therapeutics Inc. for $7.22 per share, valuing the company at approximately $469 million. The offer represents a 30% premium over Sage's closing price, leading to a 34% increase in Sage's stock price during after-hours trading. Sage, known for developing Zurzuvae, the first and only oral drug approved by the FDA for postpartum depression, has confirmed receipt of the proposal. The acquisition comes after Sage has experienced setbacks and a decline in its market value, with recent financials showing a cash burn of about $110 million in expenses against $11 million in revenue for the third quarter of 2024 (3Q24), and a cash balance of approximately $560 million at the end of September 2024.
View original story
Similar markets
Completed Sale • 25%
Other Outcome • 25%
Ongoing Negotiations • 25%
Talks Abandoned • 25%
Sale completed • 33%
Negotiations extended • 34%
Negotiations fail • 33%
Deal falls through for other reasons • 25%
Helena vetoes the deal • 25%
Antonio Gracias acquires controlling stake • 25%
Other outcome • 25%
Discontinues program • 25%
Finds new partner • 25%
Continues independently • 25%
Other outcome • 25%
Delayed • 25%
Cancelled • 25%
Modified Terms • 25%
Completed • 25%
No • 50%
Yes • 50%
Deal completed with Tencent • 25%
Deal completed with another company • 25%
No deal completed • 25%
Other outcome • 25%
No change in ownership structure • 25%
Ubisoft taken private without majority change • 25%
Tencent acquires majority stake • 25%
Another company acquires majority stake • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Other • 25%
AstraZeneca • 25%
Discontinued Products • 25%
Full Integration • 25%
Partial Integration • 25%
Independent Operation • 25%